Fesoterodine Fumarate
Brand Names: Toviaz
Methodology & AI Transparency ⓘ
Fesoterodine Fumarate Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Fesoterodine fumarate extended-release tablets are indicated for the treatment of: Overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency.
- 2 Real-world patient consensus: 89% patient "Worth It" rating across 11 anonymous logs for Fesoterodine Fumarate (RxNorm 810071).
- 3 Typical cash cost range: Dispensing cost comparison spans $39.95 mail/discount cash up to $97.88 uninsured retail (federal NADAC $0.7765).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Fesoterodine Fumarate: constipation (2%), dry mouth (6%), nausea (7.7%).
Ask our AI Specialists anything about Fesoterodine Fumarate
Fesoterodine Fumarate Mechanism, CYP450 Pathways & DailyMed Monograph
Fesoterodine fumarate extended-release tablets are indicated for the treatment of: Overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency. ( 1.1 ) Neurogenic detrusor overactivity (NDO) in pediatric patients 6 years of age and older and weighing greater than 25 kg. ( 1.2 ) 1.1 Adult Overactive Bladder Fesoterodine fumarate extended-release tablets are indicated for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency.
12.1 Mechanism of Action Fesoterodine is a competitive muscarinic receptor antagonist. After oral administration, fesoterodine is rapidly and extensively hydrolyzed by nonspecific esterases to its active metabolite, 5-hydroxymethyl tolterodine, which is responsible for the antimuscarinic activity of fesoterodine. Muscarinic receptors play a role in contractions of urinary bladder smooth muscle. Inhibition of these receptors in the bladder is presumed to be the mechanism by which fesoterodine produces its effects.
Clinical clearance of Fesoterodine Fumarate (FDA Prescription Therapeutic Agent) relies on phase i/ii hepatic conjugation of fesoterodine fumarate coupled with glomerular and tubular renal excretion with a Approximately 3–14 hours terminal plasma half-life for Fesoterodine Fumarate half-life; patients absorbing at ~52% systemic bioavailability (Fesoterodine Fumarate) bioavailability typically observe target onset around peak plasma concentration (tmax) reached 1–3 hours post-dose for fesoterodine fumarate.
FDA clinical labeling for Fesoterodine Fumarate restricts administration in reactions have included angioedema .; prior anaphylaxis, angioedema, or severe hypersensitivity to fesoterodine fumarate or fesoterodine fumarate excipients across 4 mg/1 Tablet, Extended Release, 8 mg/1 Tablet, Extended Release, 8 mg/1 Tablet, Film Coated, Extended Release, 4 mg/1 Tablet, Film Coated, Extended Release, with self-reported patient tracking dominated by nausea (7.7% of reports), headache (6.7% of reports), dizziness (6% of reports).
Avoid overlapping fda prescription therapeutic agent prescriptions alongside Fesoterodine Fumarate to prevent cumulative receptor toxicity.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Fesoterodine Fumarate dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Reactions have included angioedema .
- Prior anaphylaxis, angioedema, or severe hypersensitivity to Fesoterodine Fumarate or Fesoterodine Fumarate excipients
Logged Side-Effect Incidence (11 Reports)
Fesoterodine Fumarate Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Fesoterodine Fumarate)
Human clinical trial evidence for Fesoterodine Fumarate is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Fesoterodine Fumarate Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.7765/unit (~$23.29/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $97.88 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 11 Anonymous DotMD Community Micro-Logs | $39.95 / mo | View logs ↓ |
Fesoterodine Fumarate Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Fesoterodine Fumarate RxNorm Concept ID | 810071 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.7765 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $97.88 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $39.95 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 89.00% Worth It (11 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Fesoterodine Fumarate Patient Community, Cohort Filters & Dosage Logs
Cross-verified Fesoterodine Fumarate (fda prescription therapeutic agent) monograph synthesizing RxNorm 810071, openFDA FAERS signals, and $39.95–$97.88 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Fesoterodine Fumarate community threads and patient logs by age, biological sex, dosage, and treatment duration.